Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Shen Lian Biomedical's quarterly market cap
declined
from Sep. 2025 (¥4,348.7 Mil) to Dec. 2025 (¥3,646.5 Mil) and
declined
from Dec. 2025 (¥3,646.5 Mil) to Mar. 2026 (¥3,543.9 Mil).
Shanghai Shen Lian Biomedical's annual market cap
declined
from Dec. 2023 (¥3,071.6 Mil) to Dec. 2024 (¥2,246.2 Mil) but then
increased
from Dec. 2024 (¥2,246.2 Mil) to Dec. 2025 (¥3,646.5 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Shanghai Shen Lian Biomedical's Enterprise Value for Today is ¥3,311.4 Mil.
Shanghai Shen Lian Biomedical (SHSE:688098) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Shanghai Shen Lian Biomedical Market Cap Related Terms
Shanghai Shen Lian Biomedical Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:688098 vs VRTX, REGN, ALNY: Market Cap Comparison
For the Biotechnology subindustry, Shanghai Shen Lian Biomedical's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Shen Lian Biomedical Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Shen Lian Biomedical's Market Cap distribution charts can be found below:
* The bar in red indicates where Shanghai Shen Lian Biomedical's Market Cap falls into.
Shanghai Shen Lian Biomedical Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Shen Lian Biomedical (SHSE:688098) has a Market Cap of ¥3,449.4 Mil as of Jul. 21, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Shen Lian Biomedical and its competitors. According to the industry distribution chart, Shanghai Shen Lian Biomedical ranks #396 out of 1423 companies in the Biotechnology industry, placing it in the top 27.8%.
Is Shanghai Shen Lian Biomedical's Market Cap too high?
Shanghai Shen Lian Biomedical's current Market Cap is ¥3,449.4 Mil. Based on the distribution chart, Shanghai Shen Lian Biomedical ranks #396 out of 1423 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Shanghai Shen Lian Biomedical has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Shanghai Shen Lian Biomedical's Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Shen Lian Biomedical ranks #396 out of 1423 companies for Market Cap. This puts Shanghai Shen Lian Biomedical in the upper half of its industry. The industry median Market Cap is 111.61. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 111.61, based on 1,423 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Shanghai Shen Lian Biomedical and its competitors. For the Biotechnology industry, the median Market Cap is 111.61 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Shanghai Shen Lian Biomedical's current Market Cap is ¥3,449.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Shen Lian Biomedical stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical (SHSE:688098) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥5.86, compared to a current price of ¥8.40 — trading 43.3% above its estimated fair value. The current Market Cap is ¥3,449.4 Mil. Shanghai Shen Lian Biomedical's overall GF Score™ is 69/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Shanghai Shen Lian Biomedical (SHSE:688098), the current Market Cap is ¥3,449.4 Mil as of Jul. 21, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Shen Lian Biomedical (SHSE:688098) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Shen Lian Biomedical stock appears to be overvalued.
The current stock price of ¥8.40 is trading 43.3% above its estimated GF Value™ of ¥5.86.
GuruFocus considers Shanghai Shen Lian Biomedical to be Significantly Overvalued.
Key valuation signals for SHSE:688098:
Market Cap: ¥3,449.4 Mil
GF Value™: ¥5.86 vs. price of ¥8.40 (43.3% above fair value)
No single metric tells the full story. See the SHSE:688098 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Shen Lian Biomedical Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:688098 has been successfully added to your 
